2 3

1

A simple, sensitive and quantitative FACS-based test for SARS-CoV-2 serology in humans and animals

- 4 Agnès Maurel Ribes¹⁺, Pierre Bessière²⁺, Jean Charles Guéry³, Eloïse Joly
- 5 Featherstone⁴, Timothée Bruel⁵, Remy Robinot⁵, Olivier Schwartz⁵, Romain
- 6 Volmer², Florence Abravanel^{3,6}, Jacques Izopet^{3,6} and Etienne Joly⁷*
- 7
- 1 : Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Toulouse,
- 9 31000, Toulouse, France
- 10 2 : Ecole nationale vétérinaire de Toulouse, Université de Toulouse, ENVT, INRAE,
- 11 IHAP, UMR 1225, Toulouse, France
- 12 3 : Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity),
- 13 Université de Toulouse, INSERM, CNRS, UPS, 31300 Toulouse, France
- 14 4 : York University Hospital, York YO31 8HE, UK
- 15 5: Institut Pasteur, Virus and Immunity Unit, CNRS-UMR3569, Paris, France
- 16 6: Université de Toulouse, INSERM, CNRS, UPS, 31300 Toulouse, France
- 17 7: Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse,
- 18 CNRS, Toulouse, 31000, France
- 19
- 20 +: AMR and PB made equivalent contributions to this work.
- 21 *: correspondence to EJ: atnjoly@mac.com
- 22

23 Abstract

24 Serological tests are important for understanding the physiopathology and following the

25 evolution of the Covid-19 pandemic. Assays based on flow cytometry (FACS) of tissue culture

26 cells expressing the spike (S) protein of SARS-CoV-2 have repeatedly proven to perform slightly

- 27 better than the plate-based assays ELISA and CLIA (chemiluminescent immuno-assay), and
- 28 markedly better than lateral flow immuno-assays (LFIA).
- Here, we describe an optimized and very simple FACS assay based on staining a mix of two
- 30 Jurkat cell lines, expressing either high levels of the S protein (Jurkat-S) or a fluorescent protein
- 31 (Jurkat-R expressing m-Cherry, or Jurkat-G, expressing GFP, which serve as an internal negative
- 32 control). We show that the Jurkat-S&R-flow test has a much broader dynamic range than a
- 33 commercial ELISA test and performs at least as well in terms of sensitivity and specificity. Also, it
- 34 is more sensitive and quantitative than the hemagglutination-based test HAT, which we
- 35 described recently. The Jurkat-flow test requires only a few microliters of blood; thus, it can be
- 36 used to quantify various Ig isotypes in capillary blood collected from a finger prick. It can be
- 37 used also to evaluate serological responses in mice, hamsters, cats and dogs. FACS tests offer a
- 38 very attractive solution for laboratories with access to tissue culture and flow cytometry who
- 39 want to monitor serological responses in humans or in animals, and how these relate to
- 40 susceptibility to infection, or re-infection, by the virus, and to protection against Covid-19.
- 41

42 Introduction

43 Over the past year, our world has been thrown into disarray by a pandemic caused by a new 44 coronavirus, SARS-CoV-2. With a mortality rate around 1%, this new virus is not as pathogenic as 45 previous coronaviruses such as SARS-CoV (9.6%) and MERS (35%), but it transmits faster from 46 hymen to hymen (Sani et al. 2020), methods hyperbolic as a previous of a large previous of a large previous of a large previous faster from

- 46 human-to-human (Fani et al. 2020), probably because of a large proportion (ca. 50%) of
- 47 asymptomatic carriers (Wu et al. 2021; Long et al. 2020). Consequently, in less than two years
- 48 since its discovery in Wuhan, China, SARS-CoV-2 has spread all over the world and caused more
- 49 than 200 millions confirmed cases and over 4 millions confirmed deaths (

50 <u>https://www.who.int/emergencies/diseases/novel-coronavirus-2019</u>).

- 51 Biotechnology has proven a great asset in combating the pandemic, with the rapid 52 development of diagnostic tests and, more recently, of vaccines. Diagnostic tests detect directly 53 either the viral nucleic acid or viral proteins in nasopharyngeal swabs. Serological tests, by 54 contrast, detect antibodies developed in response to infection by the virus or vaccination, or a combination of the two. Since the presence of antibodies in serum usually correlates with 55 56 elimination of the virus and the patient's recovery, serological tests have not been very helpful 57 in the clinic. They have, however, proven an essential tool to follow the spread of the pandemic 58 by evaluating seroprevalence in populations, and they are now set to become essential to 59 evaluate the immunity of individuals as well as populations (Koopmans and Haagmans 2020). 60 61 Whilst several thousands of serological studies have been published by now, based on tests 62 performed in many millions of individuals, those myriad studies mostly document the seroprevalence in certain populations at a given time (Chen et al. 2021), but information 63 regarding the actual protection afforded by immunity after infection by SARS-CoV-2, and how 64
- 65 this correlates with the presence of antibodies against the SARS-2 virus is only just starting to
- 66 come out (Lumley et al. 2021; Letizia et al. 2021; Abu-Raddad et al. 2021; Jeffery-Smith et al.
- 67 2021; R. A. Harvey et al. 2021; Garcia-Beltran et al. 2021).).

While these recent publications show that the presence of antibodies does correlate with 68 69 protection against the Covid-19 disease, and in particular against the more serious forms of the 70 disease, one of the more burning questions that remains to be answered is how long this 71 protection will last? Another crucial question concerns whether there will be differences in the 72 duration of this protection depending on which vaccine was used, and whether an individual 73 had been infected by the SARS-CoV-2 virus before, or after, being vaccinated. 74 75 Obtaining answers to this type of questions should be greatly facilitated by access to simple, 76 cheap and quantitative serological tests, which would work both in humans and in animal 77 models. To date, however, although a multitude of commercial serological tests have been 78 developed to detect the presence of antibodies in the serum of patients (Farnsworth and 79 Anderson 2020), those are mostly ill-suited for use in research laboratories, not only because of 80 their price, but also because they are not or only poorly quantitative. 81 82 The most commonly used methods for Covid-19 serodiagnostic are either ELISA (Enzyme-83 Linked ImmunoSorbent Assays) or CLIA (ChemiLuminescent ImmunoAssays). Whilst those 84 methods show very good sensitivity and specificity, they also have several significant 85 drawbacks: i) The commercial versions are based on using volumes of serum or plasma which exceed the 86 87 amounts which can be readily obtained by finger prick, and therefore require venipuncture, 88 and hence trained personnel to collect the samples, and elaborate logistics to handle those 89 samples. 90 ii) They are relatively expensive (ca. 500 € per plate of 90 tests for commercial ELISA or CLIA) 91 and not easily modular (i.e. a whole plate will often have to be used even if only a few tests 92 are to be performed). Whilst in-house ELISAs are a possible alternative, they are difficult to 93 standardize and require high amounts of recombinant antigen (Amanat et al. 2020). 94 iii) Whilst ELISA tests are quantitative, they tend to saturate rapidly, and thus show a relatively 95 limited dynamic range. iv) Most commercial versions are designed to detect human antibodies, and thus cannot be 96 97 used to follow serological responses in animal models. 98 99 Early in the pandemic, because they could be used in a point of care setting on capillary 100 blood obtained by finger pricks, lateral-flow immune assays (LFIA) attracted considerable 101 attention as an alternative to the ELISA or CLIA plate-based methods. Dozens of versions were 102 developed by various commercial companies, and despite their relatively high price, such LFIAs 103 were used in scores of studies to evaluate the prevalence of sero-conversion in various 104 populations. Over time, however, the general performances of LFIAs have proven to be too low, 105 both for sensitivity and reliability, to be of real use in clinical settings, and even for 106 epidemiological studies (Adams et al. 2020; Mohit et al. 2021; Dortet et al. 2021; Moshe et al. 107 2021). 108 109 As an alternative to those various serological tests, we set out to develop a serological test based on hemagglutination, with the aim of obtaining a method that would be both sensitive, 110 cheap, and could be used both in the laboratory, in field settings or as a point of care test, 111 112 without the requirement for any elaborate equipment. The HAT (HemAgglutination Test)

113 method is based on a single reagent, IH4-RBD, which binds to human red blood cells (RBC) via

the IH4 nanobody specific for human Glycophorin A and coats them with the RBD domain of the

SARS-CoV-2 virus (Townsend et al. 2021). HAT has a sensitivity of 90% and specificity of 99%,

and is now used by several laboratories worldwide for epidemiological and clinical studies

(Kamaladasa et al. 2021; Jayathilaka et al. 2021; Jeewandara et al. 2021; Ertesvåg et al. 2021).
To be able to perform HAT on whole blood with the sensitivity and simplicity which we set out

119 the reach, and to attempt to make it quantitative, various modifications and improvements had

120 to be tested, and in order to do this, we felt that we needed a simple quantitative test that

121 would allow us to evaluate the amount of antibodies present in the whole-blood samples we

- were using more simply and cheaply than by using ELISA or CLIA.
- 123

124 In this regard, the S-flow test (Grzelak et al. 2020), which uses flow cytometry (FACS) 125 performed on human cells expressing the S protein, appeared as a very promising approach 126 since it is very simple to run and its performances compared favorably with three other 127 serological tests (two ELISA directed towards the S or N proteins, and a luciferase immuno-128 precipitation system (LIPS) combining both N and S detection).

The S-flow method initially described used HEK cells (Grzelak et al. 2020), which are adherent cells. We felt that it would be better to use cells growing in suspension, not only because it makes it a lot easier to grow large numbers of cells, but also because those can be used directly, without having to be detached from the plastic, which we feared could possibly alter the cells' characteristics, and introduce a possible source of variability between assays.

134 In this regard, Horndler and colleagues have recently described an assay inspired by the S-135 flow assay, but based on Jurkat cells expressing both the full-length native S-protein of SARS-136 CoV-2 and a truncated form of the human EGFR protein, which is used as an internal control for 137 the expression level of the S protein (Horndler et al. 2021).

One of the caveats of using human cells to express the S protein, however, is that those cells will also express other antigens, and MHC molecules in particular, which can be the targets of allo-reactive antibodies present in certain individuals, and not others. The background level of staining on Jurkat cells themselves will thus vary from sample to sample. To circumvent this difficulty, Pinero et al. have used the Jurkat-S+EGFR cells mixed with untransfected Jurkat cells as negative controls (Piñero et al. 2021).

Having followed the same reasoning as Horndler *et al.*, we had chosen to make use of Jurkat cells expressing the native form of the spike protein of the SARS-CoV-2 virus, but we elected to use Jurkat cells expressing the mCherry red fluorescent protein as negative controls. This is not only cheaper because it does not require labelling the cells with an additional commercial antibody, but also has the advantage of using two cell lines that are maintained in the same selective tissue culture medium.

In all three papers (Horndler et al. 2021; Piñero et al. 2021; Grzelak et al. 2020), and several
others (Egia-Mendikute et al. 2021; Hambach et al. 2021; Lapuente et al. 2021; Goh et al. 2021),
the sensitivity of approaches based on flow cytometry was reported to be superior to those of
ELISA or CLIA, probably because such tests are based on detecting the spike protein expressed
in its native conformation.

Since the Jurkat-flow test calls for the use of both a flow cytometer and cells obtained by tissue culture, it is clearly not destined to be used broadly in a diagnostic context, but its simplicity, modularity, and performances both in terms of sensitivity and quantification capacities should prove very useful for research labs working on characterizing antibody responses directed against SARS-2, both in humans and animal models.

160 **Results and Discussion**

161 162

163

Jurkat-S&R-flow: basic principles

Jurkat cells expressing high levels of the SARS-CoV-2 spike protein, which we subsequently refer to as Jurkat-S, or J-S, were obtained by means of transduction with a lentiviral vector, followed by three rounds of cell sorting. A second population of Jurkat cells, in which all cells express the mCherry fluorescent protein, and which we subsequently refer to as Jurkat-R, or J-R, was also obtained by lentiviral transduction (see M&M: Materials and Methods section).

- For the Jurkat-S&R-flow test, we simply prepare a mix of equivalent numbers of the two cells lines, J-S and J-R, and use either sera or plasma at a final dilution of 1/100 to label 2.10⁵ cells of this mix (see M&M for details). After this primary step of labelling, the cells are washed before being incubated with a fluorescent secondary antibody, and a final wash is performed before analysis by flow cytometry.
- 175

The advantage of using such an approach is that it guarantees that the test cells (Jurkat-S) and the control cells (Jurkat-R) are labelled in exactly the same conditions. Comparing the levels of staining between test and control cells can then be carried out without any risk of a difference between the two being due to a difference in the course of the labelling procedure (e.g. certain samples receiving less of the primary or secondary antibodies). Accessorily, another significant advantage of such an approach is that it reduces the number of FACS samples to be processed by a factor of two.

183

184 The mCherry signal allows simple separation by gating during analysis of the control cells 185 from the test cells (Figure 1). In samples labelled just with the secondary antibody (neg. cont.) or with pre-pandemic plasma which does not contain antibodies against the spike protein (neg 186 plasma), similar green signals are found on J-S et J-R populations. When there are antibodies 187 188 against the spike protein present in the plasma or serum used to label the cells, this will result in 189 a marked difference in the green signals detected on the J-S cells compared to the J-R cells. The 190 difference in the fluorescence intensity between the two populations will provide a quantitative 191 evaluation of the amounts of antibodies in the serum or plasma used to label the cells (first 192 column). The numbers shown in red correspond to the relative specific staining (RSS = signal J-S 193 - signal J-R / signal neg. cont.).



196 Figure 1: Basic principle and examples of the Jurkat-S&R-flow test 1718 197ⁿ A 50/50 mW of Jurkat cells expressing either the S protein of the SARS-CoV-2 virus or the mCherry 198 protein is first incubated with a 1/100 dilution of the plasma or serum sample to be tested, followed by 199 incubation with a green fluorescent secondary antibody. The cells are then analyzed by flow cytometry. 200 The panels on the first line show the gating strategy, using as an example the sample of a negative 201 control, stained only with an anti-human pan specific secondary antibody conjugated to alexa-488 : Live 202 cells are first selected on a combination of two gates drawn on three parameters: size (FSC), granularity 203 (SSC), and far red fluorescence (FL4) to eliminate the dead cells labelled by the Topro3 live stain. Jurkat-S 204 are then distinguished from Jurkat-R cells using the red fluorescence of the latter, by means of a gate drawn on a FL1/FL3 dotplot. The gates had to be drawn that way to accommodate the fact that, for the 205 206 brightest cells, the green fluorescent signal of alexa-488 can 'bleed' into the FL3 channel, and the 207 Cellquest software does not allow for FL3/FL1 compensation. A histogram overlay is then drawn with the 208 cells falling in each of these two gates (red: Jurkat-R, green: Jurkat-S). The numbers in the upper right 209 corners of those histograms correspond to the GMFIs of the two histograms.

The red numbers shown to the left of the plots correspond to the relative specific staining (RSS; i.e.
the difference of signal between J-S and J-R divided by the GMFI of the negative control, i.e. 2.00)

The first column shows examples of staining with 4 different plasmas which were either negative, or
 weakly, positively and strongly reactive with the spike protein.

The second column shows an example of the Jurkat-S&R-flow test capacity to perform a rough evaluation of the relative proportion of the various Ig isotypes in a sample, in this case the 20/130 reference serum obtained from the NIBSC.

The third column presents examples of some of the rare samples which showed various levels of alloreactivity against the Jurkat cells themselves. Although the sample on the third line had an RSS of 30 (thus well above the threshold of 20 set for positivity), this sample was probably negative since it showed no reactivity in the other two serological tests. The sample on the fourth line shows that some sera can be both allo-reactive against the Jurkat cells, and strongly reactive against the spike protein.

If isotype-specific secondary reagents are used, an evaluation of the respective amounts of various classes of antibodies can also be obtained (second column). It should, however, be noted that, because different secondary reagents do not necessarily recognize the various Ig isoforms with the same efficiency, this provides only a very rough analysis of the relative amounts of Ig-G, -A and -M. Within a set of samples, however, this can provide very simple means to compare samples with one another (Table S1).

229

230 As alluded to in the introduction, one of the possible caveats of using a human cell line to express the S protein is that some blood samples will contain allo-reactive antibodies directed 231 232 against that cell line, possibly as a consequence of a pregnancy, or past history of receiving a 233 blood transfusion or organ transplant (Hickey et al. 2016; Karahan et al. 2020). The third column 234 of Figure 1 shows examples of such samples containing marked levels of alloreactive antibodies, 235 i.e. samples for which the J-R cells show significant levels of staining compared to the same cells 236 labelled with just the secondary antibody. Based on our results collected on more than 350 237 clinical samples, we evaluate that ca. 30 % of samples will contain allo-reactive Abs that will 238 result in levels of staining of Jurkat cells that are more than five-fold that of the signal obtained 239 for the negative control (and 3-6 % more than ten-fold). Of note, we did not notice an increased 240 frequency of allo-reactivity in samples from women compared to men, which suggests that allo-241 reactivity after pregnancy is not a major cause in the origin of those allo-reactions.

242

243 A difficult question with all serological tests is that of where to set the threshold beyond 244 which the specific signals detected can confidently be considered as positive, which will be 245 directly linked to the balance between sensitivity and specificity of the assay. Based on the 246 analyses of various cohorts of positive and negative samples (some of which will be presented 247 further down in this manuscript), for the Jurkat-S&R-flow, we have settled for a threshold of RSS 248 =20, i.e. twenty-fold the value of the negative control stained just with secondary-antibodies. 249 The reason for using the geometric mean of fluorescence intensity (GMFI) of the negative 250 control as an internal reference is that, in flow cytometry, the numerical values of fluorescence intensities will be totally dependent upon the cytometer settings, and the voltages applied to 251 252 the PMT in particular. But we find that this can be somewhat compensated by such an 253 approach. For example, in the conditions used in our experiments, the GMFI of the negative 254 control had a value of ca. 2 when analyzed on a FACScalibur flow cytometer. With a threshold 255 set at 20, samples were thus considered as positive if the difference in the GMFI of the J-S and J-256 R populations was above 40 (numbers shown in red in Figure 1 are J-S - J-R / 2). When the very 257 same samples were analyzed on a Fortessa flow cytometer (Figure S1), the value of the GMFI for 258 the negative control was 24-fold higher, but the RSS values obtained closely resembled those 259 obtained with the same samples on the FACScalibur (red numbers in Figure S1 and Figure 1: 260 20/23; 366/378; 916/855; 490/508).

261

For the samples showing high levels of allo-reactive staining, however, it is worth underlining that this threshold of 20 had to be considered with some caution. Indeed, in those allo-reactive samples, such as the examples shown in the right column of Figure 1, we found that the difference between the green signals recorded for the J-S and J-R populations can fluctuate between experiments, presumably because those signals correspond to the recognition by alloreactive antibodies of cell surface markers that are not always expressed at the same levels in all Jurkat cells. Such alloreactive signals can be higher in J-R for certain serum or plasma

269 samples, or in J-S for other samples (first vs second and third line), without, in this latter case, 270 necessarily corresponding to bona-fide reactivity against the spike protein of the SARS-CoV2 271 virus. The sample shown on the fourth line represents the most extreme case we have come 272 across, from a Covid-19 patient with extremely high allo-reactivity, coupled to bona fide 273 reactivity against the spike protein. All in all, it is simply worth underlining that, for the small 274 percentage of samples showing significant alloreactivity against Jurkat cells, and staining of 275 Jurkat-S slightly higher than that of Jurkat-R, their reactivity should be checked with a different 276 serological test before considering them as truly positive.

277

278 Inspection of the dot plot for this very alloreactive sample provides the explanation for the 279 slightly odd shapes of the FL1/FL3 gates we used to discriminate Jurkat-S from Jurkat-R cells. 280 This was necessary because, on the FACScalibur, the fluorescent signal of mCherry is best 281 captured by the FL3 channel, but the version of the Cellquest program used for acquisition on 282 this cytometer does not allow for FL3/FL1 compensation. Consequently, samples with extremely 283 high FL1 signals showed some 'bleeding' into the FL3 channel. We found that this could not be 284 satisfactorily treated by post-acquisition compensation with the Flowjo analysis software either, 285 and thus resorted to drawing such gates to separate J-S from J-R populations.

286

287 We had elected to use a green/red combination for test and control cells for two reasons: 1) 288 secondary antibodies labeled with green fluorescent dyes such as fluorescein or Alexa 488 are 289 the most commonly available, and also usually the cheapest. 2) All flow-cytometers, even the 290 most basic ones, are equipped with a 488 nm laser which allows to perform green/red analyses. 291 Another important consideration is that one of the goals of this study was to set up a test which 292 could be used by as many research teams as possible, including those based in institutes from 293 less affluent countries, which are less likely to have access to recent, state-of-the-art multi-laser 294 flow cytometers. As will be seen later, with secondary antibodies conjugated to Alexa-647 which 295 can be excited by the second 633 nm laser of the FACScalibur, it is possible to use Jurkat-GFP 296 cells as an alternative to J-R cells.

297

When the same samples as shown on Figure 1 were analyzed using a Fortessa flow cytometer, the picture was quite different (Figure S1). This more recent flow cytometer is endowed with several lasers, including a 561 nm Yellow-Green laser, which is much better suited for the excitation of the mCherry fluorescent protein, thus yielding much higher signals which, since they are acquired on a different laser line from the green signals, require absolutely no compensation.

304

305 In many flow cytometry facilities, users are required to fix any samples that have been in 306 contact with materials of human origin. Whilst this was not the case for us, we still tried 307 analyzing the same samples after those were fixed with 1% formaldehyde and kept for 4 days at 308 4°C before re-analysis. As can be seen on the right part of Figure S1, formaldehyde-fixation 309 resulted in a 7-fold drop in the intensity of the mCherry signals, which made it impossible to 310 separate J-R from J-S populations on the FACScalibur (first line). On the other hand, analysis on the Fortessa was still comfortably possible. Of note, whilst formaldehyde did not noticeably 311 312 alter the fluorescence signals of the alexa-488 dye, it did result in a twofold increase of the 313 green auto-fluorescence of the negative controls, hence resulting in a twofold reduction of the 314 RSS compared to those obtained on unfixed cells.

- 315 Performance of the JurkatS&R-flow test on clinical samples
- 316

317 Next, we compared the performance of the Jurkat-S&R-flow test with those of two other 318 serological tests: the Wantai commercial RBD ELISA test, and the hemagglutination-based test, 319 HAT (Townsend et al. 2021).

- 320
- 321 For this, we made use of two cohorts of clinical samples.

322 First, a preexisting cohort of 121 sera available in the virology laboratory of the Toulouse 323 hospital which had all previously been tested with the Wantai RBD ELISA test (Abravanel et al. 324 2020), comprising 40 negative serum samples collected before December 2020, and 81 sera 325 from PCR-positive subjects. For those samples, RBCs from O- donors were used to perform the 326 HAT tests (see M&M).

327 The second cohort consisted of 267 whole blood samples collected on EDTA, obtained from 328 the hematology department of the Toulouse hospital as left-over clinical material, for which we 329 have consequently very little clinical information. For those samples, the HAT test was 330 performed on whole blood, i.e. using the subjects' own RBCs for hemagglutination. The blood 331 samples were subsequently centrifugated, and the plasmas collected to perform the Jurkat-332 S&R-flow and the RBD-ELISA tests.

333

336

334 The result of the analysis of these two cohorts with the three serological tests are presented 335 in Figure 2, with colors used to represent the HAT results.



550	
339	Figure 2: Comparison of the results of the 3 serological tests on two cohorts of clinical samples.
340	Panel A: results obtained with a cohort of 121 serum samples (81 PCR pos, 40 neg) collected by the
341	virology department of the Purpan Hospital (Toulouse, France).
342	Panel B: results obtained with a cohort of 267 whole blood samples coming from the hematology
343	department of the Rangueil Hospital (Toulouse, France).
344	Each plot presents ELISA scores (Y axis) against the results of the Jurkat-S&R-flow tests, expressed as RSS.
345	For improved clarity, both axes are presented on log scales (for this, the negative RSS values of 4 samples
346	of the cohort on the right had to be manually converted to a value of 0.5).
347	Colors are used to represent the HAT results: red: positive, blue: negative, yellow: partially positive
348	hemagglutination, black: false positive, i.e. samples for which hemagglutination also occurred with the
349	IH4 nanobody not coupled to the RBD domain.

350 The results of the first cohort (Figure 2A) show a clear-cut dichotomy in the distribution of 351 the points, with two well separated clouds: one of blue points falling in the lower left quadrant, 352 and one of red points in the upper right one. In other words, for this cohort of sera collected 353 either from hospitalized Covid-19 patients or dating from before the pandemic for the negative 354 controls, the three tests are in almost perfect agreement for the discrimination between 355 positives and negatives, with just one yellow point in the lower right quadrant, i.e. positive for 356 the Jurkat-S&R-flow test, showing only partial hemagglutination, but the signal for the RBD-357 ELISA test falling slightly below the threshold of 1 set by the manufacturer, suggesting that the 358 anti-viral serological response of this subject was probably focused on regions of the spike 359 protein outside of the RBD domain.

360

361 Of note, partial hemagglutination was also recorded for two other samples which were 362 negative for the two other tests. Those two samples were from a group of 38 patients 363 hospitalized for Covid-19, but for whom the blood had been collected less than 14 days after the 364 PCR diagnostic. This observation is in line with our previous observation that the HAT test may 365 be particularly performant for the detection of early serological responses, probably because of 366 a higher hemagglutinating capacity of IgMs (Townsend et al. 2021). Incidentally, in this same 367 group of 'early' PCR-positive Covid patients, there were also 4 other samples which were 368 negative for all three tests (see tables of data provided as supplementary material). 369

370 The results of the second cohort, which comprised a few Covid patients, but also a large 371 proportion of blood samples randomly picked among those from patients hospitalized for 372 conditions unrelated to Covid-19, yielded a much less clear picture than the first one. As can be 373 seen on Figure 2B, many of the dots for this cohort occupy a more intermediate position 374 between the two clouds of clearly positive and clearly negative samples. In the upper right 375 guadrant, one notices a relatively high proportion of blue and yellow spots, i.e. of HAT negative 376 or partial samples in the set which were positive with both the RBD-ELISA and Jurkat-S&R-flow 377 tests, albeit in the lower left part of the quadrant, i.e. rather weakly.

378

On the other hand, there are also a handful of samples in the lower left quadrant for which partial or full hemagglutination was detected, which may correspond to early serological responses. There are also a few blue dots in the upper left and lower right quadrant, thus corresponding to samples being positive only either with the RBD ELISA or the Jurkat-S&R-flow test. According to previous work, the sera which react weakly on the full length spike protein expressed at the surface of Jurkat cells are most likely due to cross-reactivities with the S2 domain of other coronaviruses (Ng et al. 2020; Khan et al. 2020).

386

One additional conclusion that can be drawn from the comparison of the results of the RBD ELISA with those of the Jurkat-S&R-flow test is that, whilst the two methods show similar
 sensitivities, the ELISA signals tend to saturate very rapidly, and are thus much less dynamic that
 those obtained by flow cytometry.

- 391
- 392

393 394

Examples of possible uses of the Jurkat-flow test

395 A further advantage of the Jurkat-S&R-flow test compared to the commercial RBD-ELISA we 396 used for this study is that it only requires 1 μ L of plasma or serum, compared to 100 μ L for the 397 ELISA, which makes it possible to perform on small volumes of capillary blood collected by finger 398 prick.

399

400 As a proof of concept that this was doable and useful, we used capillary blood which one of 401 the authors collected by pricking his finger at various intervals to document the time course of 402 his serological response after vaccination, and the results are shown in panel A of Figure 3. One 403 somewhat surprising finding was with the low levels of IgM recorded, which may in part be 404 explained by the fact that, as a rule, anti-IgM secondary antibodies tend not to work as well as 405 those against the other isotypes. One should note, however, that, with the same anti-IgM 406 secondary reagent, signals of the same order of magnitude were found for IgG and IgM with the 407 20/130 reference serum (Figure 1), as well as in several other samples (Table S1). The 408 observation that the signals obtained with an anti-IgG reagent are similar, and even often a bit 409 higher to those obtained with the pan-reactive anti-IgGAM is something which we tend to find 410 in most samples (Table S1), and which had already been underlined by Grzelak et al. in the 411 context of the S-flow test (Grzelak et al. 2020).

412

413 The capacity of the SARS-CoV-2 virus to infect primates, hamsters or ferrets has provided 414 very useful animal models to understand the physiopathology of Covid-19, whilst its capacity to 415 infect domestic pets such as cats and dogs does raise concerns about the transmissions of the 416 virus back to humans, as well as about the problem of animal reservoirs from which it will be 417 very difficult to eradicate the virus. Whilst scores of commercial and lab-made methods have 418 been described to follow human serological responses to the virus, there is a remarkable 419 paucity of tests available today applicable to animals. Since all it would take to adapt the Jurkat-420 S&R-flow test to animals would be to use different species-specific secondary antibodies, we 421 explored whether this would work for mice, cats, dogs and hamsters. 422



Figure 3: Various examples of the possible uses of the Jurkat-flow test

Panel A: Monitoring serological responses in humans

The Jurkat-S&R-flow test was used to follow the serological response of an individual during the course of his vaccination (red arrows: first injection on day 0 and boost on day 27), with isotyping using specific secondary reagents performed as described in the M&M section. Y axis: Specific staining (GMFI J-S – GMFI J-R)

Panel B: The Jurkat-S&R-flow test can be used to follow Ig responses in mice.

Sera from three groups of mice having been immunized either once, twice or not by intra-peritoneal injection of inactivated SARS-CoV-2 virus were analyzed with the Jurkat-S&R-flow test, using an anti-mouse Ig secondary antibody. Y axis: GMFI on Jurkat-R (blue columns), on Jurkat-S (top of green columns), The specific signals correspond to the yellow or green portions (GMFI J-S – GMFI J-R).

Panel C: In cats and dogs, the results of the Jurkat-S&R-flow test correlate with those of seroneutralization titers.

Panels of sera from cats and dogs whose owners had recovered from symptomatic Covid-19 were used to perform both sero-neutralization assays and the Jurkat-S&R-flow test, using the corresponding secondary antibodies. Specific stain = GMFI J-S – GMFI J-R. *: the higher SN titers shown for the cat serum 66JQ was obtained on a different day from all the others.

Panel D: Monitoring of antiviral serological responses in Hamsters with the Jurkat-S&G-flow test
 For this experiment, we used sera from 6 hamsters which had been experimentally infected with the
 UCN1 strain of SARS-CoV-2 15 days earlier, as well as 6 uninfected controls. Since we had an anti hamster Ig secondary antibody conjugated to alexa 647, we used an S&G version of the test, with Jurkat
 cells expressing GFP as negative control, and propidium iodide to gate out dead cells (see M&M). As can
 be seen on the right side of the panel, in this configuration, no compensation was required, and
 separating the Jurkat-S test cells from the Jurkat-G control cells could be performed with simple square
 gates. And although the GFP signal was reduced after fixation of the cells in PFA for 24 hours analysis of
 cells was still possible with the FACScalibur, with almost no loss of the alexa 647 signal.

452 First, we used sera of mice which had been immunized once or twice with inactivated SARS-453 CoV-2 virus injected intra-peritoneally. As can be seen on panel B of Figure 3, whilst the sera of 454 control mice did not react significantly with Jurkat cells, those of immunized mice showed 455 strong specific reactions against the spike protein, which were even higher in those having 456 received two injections. Of note, the reactions against the Jurkat-R cells also went up in 457 correlation with the injections, albeit to a much lesser degree than against the S protein. This is 458 presumably due to the fact that the preparations of inactivated virus used for the 459 immunizations probably contained some bovine proteins from the serum used in the tissue 460 culture medium that would have the capacity to bind to the surface of the Jurkat cells, such as, 461 for example, beta-2-microglobulin binding to MHC class I molecules. The Jurkat-S&R-flow 462 method therefore seems to work very satisfactorily in mice, and since it requires only a few μ L 463 of blood, it is well suited to follow serological responses over time.

464

465 We then turned our attention to cats and dogs, which have both been shown to be 466 susceptible to infections by the SARS-CoV-2 virus (Sit et al. 2020; Dróżdż et al. 2021; Bessière, 467 Fusade-Boyer, et al. 2021; Chen 2020), but for which one of the only reliable means to test for 468 the presence of a serological response is to perform sero-neutralization experiments, which are 469 both cumbersome and require access to BSL-3 facilities. For our exploratory experiments, we 470 simply used sets of sera collected from 11 cats and 11 dogs whose owners had had symptomatic 471 Covid-19 infections, and on those we performed both sero-neutralization experiments, and the Jurkat-S&R-flow test, using the appropriate secondary antibodies. As can be seen on panel C of 472 473 Figure 3, we found a very good correlation between the levels of specific staining of Jurkat-S 474 cells and the neutralization titers of the same sera. Whilst those are very preliminary 475 observations which will need to be strengthened by many more samples, and in particular with 476 samples collected before the Covid-19 pandemic as negative controls, those results show that 477 the Jurkat-S&R-flow test can clearly be used to evaluate the levels of antibodies against the S 478 protein of the SARS-CoV-2 virus in cats and dogs.

479

480 Finally, we turned our attention to hamsters, which are susceptible to infection by SARS-CoV-481 2, and have been a very useful animal model to study the physiopathology of the infection. For 482 this, we made use of a panel of sera from hamsters which had been used in a previous study 483 (Bessière, Wasniewski, et al. 2021). Because we had some anti-hamster Ig conjugated to the 484 Alexa -647 fluorochrome at our disposal, we took this opportunity to test the possibility of 485 adapting the Jurkat-S&R-flow test to a Jurkat-S&G-flow test, i.e. using Jurkat cells expressing 486 GFP rather than mCherry as the internal negative control. As can be seen on panel D of figure 3, 487 the sera from the hamsters that had been experimentally inoculated with the SARS-CoV-2 virus 488 two weeks earlier all harbored very high levels of antibodies against the virus, whilst no signal 489 was detected with the sera from control animals. Of note, with the S&G version of the test, i.e. 490 using GFP-expressing Jurkat cells as negative control and a secondary antibody conjugated to 491 alexa-647, since the two signals were collected on the separate green and red laser lines of the 492 FACScalibur, the situation was similar to when we analyzed the Jurkat-S&R-flow test on a 493 Fortessa flow cytometer: gating to separate the test from the control cells was achieved with 494 simple rectangular gates, and although fixation in PFA resulted in a twofold reduction of the GFP 495 fluorescent signal, and the auto-fluorescence of the Jurkat-S cells increased about threefold, the 496 efficient triggering of GFP by the 488 nm laser meant that the test and control populations could 497 still be separated and analyzed after fixation, albeit staining with propidium iodide could no498 longer be used to gate out dead cells.

- 499
- 500 501

Concluding remarks and perspectives

502 Given its versatility, flexibility and affordability, we believe that the Jurkat-S&R-flow or 503 Jurkat-S&G-flow assays could prove useful for many research scientists wanting to measure 504 serological responses directed towards the spike protein of the SARS-CoV-2 virus, either in 505 humans, or in animals, but who would not have either the financial means to purchase 506 commercial plate-based assays such as ELISA or CLIA, or access to the sizeable amounts of 507 recombinant proteins required to set those up in-house. The Jurkat-flow tests could be 508 performed by any laboratory with access to tissue culture and to a flow cytometer, at a cost of 509 roughly 10 cents per sample (see M&M for calculation). It is thus much cheaper than 510 commercial ELISAs, which cost around 500 € per plate of 90 samples. And the Jurkat-flow test is 511 also completely modular, i.e. each test only comprises the number of samples required, 512 contrary to plate-based assays for which it is rather difficult not to use up a whole plate every 513 time.

514

515 Several reports have already highlighted that using flow-cytometry for the detection of 516 antibodies binding to the S protein expressed at the surface of cells tends to perform better 517 than plate-based assays which use immobilized recombinant proteins (Egia-Mendikute et al. 518 2021; Hambach et al. 2021; Lapuente et al. 2021; Goh et al. 2021; Horndler et al. 2021; Piñero et 519 al. 2021; Grzelak et al. 2020; Ng et al. 2020). This is most likely related to the fact that many 520 antibodies will be binding to conformational epitopes, which will only be found on the naturally 521 expressed and properly folded spike protein. In this regard, the capacity of the S protein to 522 undergo structural fluctuations, particularly at the level of the RBD domain which can be in 523 either an open/up or closed/down conformation, has been shown to influence the binding-524 capacity of various antibodies (W. T. Harvey et al. 2021; Barnes et al. 2020; Robbiani et al. 2020; 525 Piccoli et al. 2020; Zhou et al. 2020; Huang et al. 2021; Dejnirattisai et al. 2021). This is 526 supported by the results shown in Figure S2, i.e. that, for most samples, we found that 527 incubation at room temperature resulted in a sizeable increase in the amounts of antibodies 528 binding to the spike-expressing cells, suggesting that, at the surface of live cells, the capacity of 529 the spike protein to fluctuate between various conformations will expose different epitopes, 530 and allow the binding of more antibodies.

531

532 One striking aspect of the results shown on Figure 2 is in the difference of performance of 533 the tests between the two cohorts of samples tested. On the one hand, nearly perfect scores 534 were obtained for all three tests on a cohort of sera comprised either of control samples 535 collected before 2019, or of positive sera from PCR-positive Covid-19 patients. On the other 536 hand, the situation was much less clear-cut for the cohort comprising blood samples picked 537 more or less randomly and blindly among those available as left-overs from the hematology 538 department and was, therefore, more akin to a 'real' population. For this second cohort, an 539 additional confounding factor may have been that, since all the samples were from hospitalized 540 patients, some sera may have been poly-reactive due to inflammatory pathologies unrelated to 541 Covid-19.

543 All in all, this difference between the two cohorts is reminiscent of the common observation 544 that the performances of clinical tests are often much lower on real populations than those 545 obtained by the manufacturers on very carefully controlled and standardized populations. Our 546 results indeed bring support to the view that the performance of any given serological test will 547 be entirely dependent on the set of samples used to measure it: whilst it is relatively easy to 548 reach an almost perfect score on a cohort comprised only of highly positive and completely negative samples such as the one used for Figure 2A, the situation becomes much less clear 549 when using a set of samples more closely resembling the general population, in which the 550 551 positive or negative nature of many samples will remain uncertain, and from which it would 552 thus seem futile to try to make precise calculations of sensitivity and specificity. This being said, 553 performing several tests in parallel on such cohorts is very useful to compare the performance 554 of those tests with one another.

555

556 Several recent reports have underlined the correlation between the serological levels of 557 neutralizing antibodies, which are mostly directed against the RBD, and the degree of protection 558 against becoming infected, or re-infected, by the SARS-Cov-2 virus (Feng et al. 2021; Khoury et 559 al. 2021; Garcia-Beltran et al. 2021). Low levels of antibodies are often found in convalescent 560 subjects following asymptomatic infections, and Kalamadasa and colleagues have shown that, 561 whilst HAT sensitivity in such individuals can be as low as 50 %, HAT results are strongly 562 correlated with the seroneutralisation activity in those samples (Kamaladasa et al. 2021). Over the coming months and years, antibodies levels will progressively decrease in both vaccinated 563 564 and convalescent people, and one of the crucial questions will be that of when to start planning 565 to administer vaccine boosts. Levels of neutralizing antibodies will certainly evolve very 566 differently in different individuals, and an additional difficult aspect will be to define rules for 567 the administration of vaccine boosts, and whether those should be defined as a general rule 568 (e.g. so many months after the initial vaccination), or individually, based on the monitoring the 569 levels of neutralizing antibodies. For such an individually-based approach, HAT would seem to 570 be a particularly appropriate solution since it is a very simple and cheap test based on the 571 binding of antibodies to the RBD domain (Townsend et al. 2021), which are those with 572 neutralizing activity. Furthermore, because the only reagent in HAT simply comprises small 573 amounts of soluble IH4-RBD protein, the hemagglutination test can be very easily adapted to 574 detect antibodies binding to variant forms of the virus (Jayathilaka et al. 2021).

575

576 Whilst HAT is not as sensitive as an anti-RBD ELISA or the Jurkat-S&R-flow test, this relatively 577 low sensitivity may not really be a problem for using HAT to help decide when to revaccinate 578 people since low levels of antibodies are unlikely to be fully protective. By performing titrations, 579 the HAT assay can also provide a quantitative assessment of the levels of circulating antibodies, 580 which have been shown to correlate strongly with sero-neutralisation titers (Lamikanra et al. 581 2021). In the current version of HAT, however, such a quantification can only be performed in a 582 laboratory environment because it requires separation of the plasma or serum from the red 583 blood cells. Making use of the Jurkat-S&R-flow test as a reference, we are currently in the 584 process of completing work on a modified version of HAT that will be compatible with being 585 performed pretty much anywhere, with no specialized equipment, and will provide a 586 quantitative evaluation of the levels of antibodies in a single step (Joly et al. man in prep.).

587 **Detailed Contributions**

588

589 Authors

Name	First name	ORCID	contributions
Maurel Ribes	Agnes	0000-0002-7560-9502	Collected and anonymized blood
			samples; scored HAT tests, corrected the
			manuscript
Bessière	Pierre	0000-0001-5657-0027	Provided hamster, cat and dog sera;
			performed SN; helped perform FACS
			assays, corrected the manuscript
Guéry	Jean Charles	0000-0003-4499-3270	Provided immunized mouse sera;
			corrected the manuscript
Joly Featherstone	Eloise	<u>0000-0001-9077-359X</u>	Scored HAT tests
Bruel	Timothée	0000-0002-3952-4261	Provided Jurkat-R and -S cells;
			corrected the manuscript
Robinot	Rémy	0000-0002-3651-0171	Transduced, selected and grew Jurkat
			cells
Schwartz	Olivier	0000-0002-0729-1475	Provided Jurkat-R and -S cells
Volmer	Romain	<u>0000-0003-1591-3251</u>	Provided hamster sera
Abravanel	Florence	0000-0002-1753-1065	Provided cohort of sera and ELISA kits
Izopet	Jacques	0000-0002-8462-3234	Provided cohort of sera and ELISA kits;
			made suggestions for the manuscript
Joly	Etienne	0000-0002-7264-2681	Designed and funded the study;
			Performed the experiments; Wrote the
			paper.

590

591 Other contributors

Townsend	Alain	Designed the IH4-RBD reagent and funded its production					
Tiong	Tan	Produced the IH4-RBD reagent					
Rijal	Pramilla	Produced the IH4-RBD reagent					
Buchrieser	Julian	Generated lentiviral vectors					
Porrot	Françoise	Grew Jurkat cells					
Featherstone	Carol	Copy edited parts of the manuscript					

592

593 Acknowledgements

594

595 The authors are extremely grateful to Alain Townsend, Tiong Kit Tan, Pramila Rijal, Julian 596 Buchrieser and Françoise Porrot, who contributed the various materials detailed in the above 597 table, and to Carol Featherstone for copy editing the manuscript. They also gratefully 598 acknowledge the contributions of Marianne Navarra, for her help in setting up the agreement 599 with the hospital; Miriam Pinilla, Karin Santoni and Etienne Meunier for the gift of Topro-3 and 600 for performing the Mycoplasma tests; Emmanuelle Naser and Pénélope Viana from the IPBS 601 flow cytometry facility for their assistance, and the very helpful staff of the Toulouse EFS. 602 Funding: The first part of this project was funded by a private donation. The second part was

603 funded by the ANR grant HAT-field to EJ.

604	Materials and Methods
605	
606	Reagents
607	
608	Polyclonal anti-human and anti-mouse Igs secondary antibodies, all conjugated to Alexa-488,
609	were from Jackson laboratories, and purchased from Ozyme (France) . Refs: anti-human Ig-
610	GAM: 109-545-064, -G: 109-545-003, -A: 109-54-011, -M: 109-545-129; anti-mouse Ig-G: 115-
611	545-003
612	
613	Anti-cat IgG (F4262) and anti-dog IgG (F7884) secondary antibodies, both conjugated to FITC,
614	were obtained from Sigma.
615	
616	Anti-hamster IgG conjugated to Alexa 647 was obtained from Invitrogen (A-21451)
617	
618	Anti RBD monoclonal antibodies: FI3A (site 1) and FD-11A (site 3) (Huang et al. 2021); C121
619	(site 2) (Robbiani et al. 2020); CR3022 (site 4) (ter Meulen et al. 2006); EY6A (site 4) (Zhou et al.
620	2020). All those were obtained using antibody-expression plasmids, as previously described
621	(Townsend et al. 2021).
622	
623	The 20/130 WHO reference serum was obtained from the NIBSC (Potters Bar, UK)
624	
625	BSA Fraction V was obtained from Sigma (ref A8022).
626	
627	PBS and tissue culture media were obtained from Gibco.
628	
629	Generation of Jurkat-S, Jurkat-R and Jurkat-G cell lines
630	All three cell lines were obtained by means of lentiviral transduction.
631	pLV-EF1a-SARS-CoV-2-S-IRES-Puro was created by cloning a codon-optimized version of the
632	SARS-CoV-2 S gene (GenBank: QHD43416.1) into the pLV-EF1a-IRES-Puro backbone (Addgene
633	plasmid # 85132 ; <u>http://n2t.net/addgene:85132</u> ; RRID:Addgene_85132) using BamHI and
634	EcoRI sites.
635	The lentiviral vector for the expression of mCherry was obtained by replacing the GFP
636	sequence of GFP by that of mCherry in the pCDH-EF1 $lpha$ -MCS*-T2A-GFP plasmid
637	(https://systembio.com/shop/pcdh-ef1α-mcs-t2a-gfp-cdna-single-promoter-cloning-and-
638	expression-lentivector/
639	Lentiviral infectious supernatants were obtained after transient transfection of HEK cells with
640	pLV- or pCDH-derived vectors, together with the packaging R8-2, and VSV-G plasmids.
641	Supernatant was harvested 24h and 48h post transfection, passed through a 45 μ m filter and
642	stored in aliquots at -80°C. For the transduction of Jurkat cells, those were distributed in a 6 well
643	plate at 1.5. 10^6 cell per well, in a volume of 500 µL of tissue cuture medium (RPMI, 10 % FCS,
644	1% PS, 2% Hepes), and 20 μ L of the infectious supernatants were added, as well as 5 μ L of
645	Lentiblast premium (OZBiosciences). The plate was then spun at 1000g for 60 min at 32°C,
646	before adding 2.5 ml of tissue culture medium and returning the plate to the 37°C incubator.
647	Selection with puromycin was then performed at a concentration of $10\mu g/mL$.
648	After a few days, the population of Jurkat cells thus obtained was stained for flow cytometry
649	analysis using a highly reactive serum from a covid-19 patient, and it was found that most cells

650 expressed the S protein, but at low to intermediate levels. To obtain a population that would 651 express higher levels, we submitted this population to three successive rounds of sterile cell 652 sorting using a FACSAria Fusion cell sorter (Beckton Dickinson), selecting each time the 5 % of 653 cells with the brightest staining. Cells were placed back in culture and reamplified after each 654 round of selection. At the time of the second round of sorting, the cell sorter was also used for 655 single cell cloning, but all of the dozen clones obtained by this means showed lower expression 656 that the sorted population. The expression of the S protein in the population of Jurkat cells 657 obtained after these three rounds of sorting was found to remain expressed in all cells, and at 658 similar levels, for more than 50 successive passages, over many weeks of continuous cell 659 culture. 660

The Jurkat-R cells were obtained by successive transduction with the pCDH-GFP lentiviral
 vector described above, then with the empty pLV lentiviral vector, followed by selection with
 Puromycin at 10µg/mL. FACS analysis revealed that the mCherry fluorescent protein was
 expressed in 100 % of the cells of the population thus obtained, which therefore did not need to
 undergo any cell sorting.

666

After the initial selection process, both the Jurkat-S and Jurkat-R cell line were maintained in
 RPMI, 10 % FCS, 2 mM Glutamine, 1% PS and Puromycin at 2.5 μg/mL. The Jurkat-S and Jurkat-R
 cell lines were both checked for the absence of mycoplasma contamination using the HEK blue
 hTLR2 kit (Invivogen, Toulouse, France).

671

677

The Jurkat-G cell line was obtained by transduction with the Trip-GFP lentiviral vector (Zennou et al. 2000). Cell sorting was used to bring the 90% of the Jurkat cells that were expressing GFP after the initial transduction to 100 %. The cells were then kept in culture for several dozen passages in standard tissue culture medium with no detectable loss of GFP expression.

678 FACS staining

Before experiments, cells in the cultures of both Jurkat-S and Jurkat-R cell lines were
counted, and sufficient numbers harvested to have a bit more than 10⁵ cells of each per sample
to be tested. Cells from both cell lines were then spun, and resuspended in their own tissue
culture medium at a concentration of 2.2 10⁶ cells/ mL before pooling equal volumes of the two.
Plasmas or sera to be tested were diluted 1/10, either in PBS or in PFN (PBS / 2% FCS / 200

 $\begin{array}{ll} \mbox{684} & \mbox{mg/L sodium azide} \). \ 10 \ \mu L \ of \ these \ 1/10 \ dilutions \ were \ then \ placed \ in \ U-bottom \ 96 \ well \ plates, \\ \mbox{before adding \ 90 \ ul \ per \ well \ of \ the \ Jurkat-S&R \ mix. \end{array}$

The plates were then incubated for 30 minutes at room temperature before placing them on ice for a further 30 minutes. As can be seen on the supplementary Figure 2, we have found that this initial incubation at room temperature results in a marked increase of the staining signals for most antibodies.

All subsequent steps were carried out in the cold, with plates and washing buffers kept on ice. After the primary staining, samples were then washed in PFN, with resuspending the cells by tapping the plate after each centrifugation, and before adding the next wash. After 3 washes, one drop (i.e. ca. 30 ul) of secondary fluorescent antibody diluted 1/200 in PFN was added to each well, and the cells resuspended by gentle shaking of the plates. After an incubation of 60 min on ice, samples were washed two more times with cold PFN
before transferring the samples to acquisition tubes in a final volume of 300 ul PFN containing
30 nM TO-PRO[™]-3 lodide (Thermo Fischer Scientific, ref T3605).

This protocol was used for staining with just one pan-specific secondary antibody, i.e. for most of the samples of this study. For specific isotyping, i.e. for staining separately with either anti-IgG, -IgA or -IgM, as well as the pan-specific anti-Ig-GAM secondary antibody, we used double the quantities of cells and of serum or plasma for the primary step, and split the samples into 4 wells after the second wash, before proceeding to the subsequent steps as for the standard protocol.

The vast majority of the experiments for this study were analyzed on a FACScalibur flow cytometer controlled by the Cellquest pro software (Version 5.2, Beckton Dickinson), using the FL1 channel for Alexa-488 or FITC, the FL3 channel for m-Cherry, and the FL4 channel (with the 633 nm laser) for live gating with the TO-PRO[™]-3 live stain.

For the samples shown on supplementary Figure 1, double quantities were used (as for isotyping) so that the same samples could also be acquired on a Fortessa flow cytometer,

710 controlled by the Diva software (Beckton Dickinson). After the samples had been run on both

711 machines, an equivalent volume of PBS with 2% formaldehyde what added to what was left in

the tubes, and those were stored at 4°C for 4 days before they were once again analyzed on both machines.

- Post-acquisition analysis of all the samples was performed using the Flowjo software (version10.7.1)
- For the Jurkat-S&G-flow test, Jurkat-R cells were replaced by Jurkat-G cells, we used a secondary antibody conjugated to alexa 647, and TO-PRO[™]-3 lodide was replaced by propidium iodide at 2 ug/ml final concentration. The samples were then analyzed on the same FACScalibur flow cytometer, using the FL1 channel for the GFP fluorescence, FL2 for live gating with propidium iodide, and FL4 for the Alexa-647 signals.
- 721 722

Cost of the Jurkat-S&R-flow test

The cost per sample of the Jurkat-S&R-flow test lies in large part with the price of the
secondary antibodies used. Typically, one vial of secondary antibody costs about 150 € for 1ml,
and using 30-50 ul at a 1/200 dilution will provide for at least 5000 samples. The cost of a
polyclonal antibody is thus of the order or 3-5 cts per sample.

Each sample requires 2.10^5 jurkat cells, which is roughly the amount obtained with 0.5 ml of standard tissue culture medium, which costs around 50 €/L, i.e. 2.5 cts/sample. All in all, if one adds the cost of TC, buffers for the washes and disposable plastics, we estimate that the cost per sample will be of the order of 10 cts.

The cost of access to a flow cytometer will be extremely variable between laboratories and
institutes. If the cost of access is 20 € per hour, and one runs 200 samples per hour, this will add
another 10 cts to the cost per sample.

734

735 HAT tests

HAT tests were performed using the IH4-RBD reagent diluted at 1 ug/ml in PBN rather than in
 straight PBS as originally described (Townsend et al. 2021), which results in a slight

improvement of the HAT performances, and much improved stability of the IH4-RBD stocks (

- Joly et al., man in prep.). PBN simply consists of PBS complemented with 1% BSA and 200 mg/L
- sodium azide. The main role of BSA is to prevent the IH4-RBD reagent from adsorbing onto the

plastic of tubes and assay plates, and the azide prevents bacterial and fungal contaminations of
 the stocks. HAT tests were all performed in V-bottom 96 wells plates (Sarstedt, ref 82 1583).

For performing HAT on sera, two tubes of suspension of RBC from an O- donor were prepared at approximately 6μ L of packed RBC per ml of PBN. The first tube was used to fill the negative control wells with 90 μ L per well. The IH4-RBD reagent was added at 1.1 ug/ml to the second tube of RBC suspension and this was dispensed at 90 μ L per test well. Sera to be tested were diluted 1/10 in PBS, and 10 μ L of the dilutions were added to a control and a test well.

For performing HAT on whole blood samples, which were all leftover clinical samples collected in EDTA tubes (purple tops), 10 μ L were diluted with 60 μ L of PBS + 5 mM EDTA, and 10 μ L of this 1/7 dilution were added to each of two wells containing either 90 μ L of PBN for the negative controls, or 90 μ L of PBN containing 1.1 μ g/mL of IH4-RBD reagent for the test wells.

752

For both sera and whole blood samples, after 60 minutes incubation at room temperature,
the V bottom plates were placed on a homemade light box tilted at an angle of approximately

10° from the vertical, and pictures taken with a mobile phone after approximately 20 seconds.

756 In an attempt to increase the sensitivity of the method by detecting partial

hemagglutinations, the plates were then returned to a horizontal position for a further twohours, and the procedure of tilting the plate and taking pictures was repeated.

As a final step, to ensure that the RBCs in all the 267 blood samples of the second cohort were expressing glycophorin, 30 ul of the monoclonal antibody CR3022 diluted at 200 ng/ml in PBN were added to all samples and resuspended by pipetting with a multichannel pipet. The plates were tilted one more after another 60 minutes, and intense hemagglutination was seen in all 267 samples.

After transferring all the pictures to computer files, the hemagglutination tests were scoredby three independent assessors, of which two were blinded.

The scoring system was as follows: A score of 1 was given only to those samples which showed complete hemagglutination after one hour. A score of 0.5 was given to samples which showed either partial hemagglutination after one hour, or partial or complete hemagglutination after the second incubation of 2 hours.

This revealed that, whilst there was 100% agreement between the three assessors for the scoring of complete hemagglutination, the scoring of partial hemagglutination proved to be much more subjective and variable, and only those samples which had been scored as partials by all three assessors were finally considered as bona fide partial hemagglutinations.

774 775

ELISA

The ELISA tests were performed using the WANTAI SARS-CoV-2 Ab ELISA (ref WS-1096),
according to the manufacturer's instructions. This commercial kit allows detection of all human
antibody isotypes recognizing a recombinant RBD domain of the SARS-Cov-2 virus.

The ELISA tests for the cohort of 121 sera were performed in the virology department of the Toulouse hospital, as described previously (Abravanel et al. 2020).

The series of ELISA tests for the cohort of 267 plasmas were performed at the IPBS, with the washes being performed by hand rather than by an automated machine, and the 450/625 ODs read by a μ Quant plate reader. All the positive samples of this cohort, as well as a set of

randomly selected negatives, were submitted to a repeat of the assay, which showed excellentreproducibility.

787 Human samples

Purpan cohort: The collection of 2019 (negative) and SARS-CoV-2 infected (positive) patients
 was obtained from the laboratory of virology of the Purpan hospital, as previously described
 (Abravanel et al. 2020).

791 Rangueil Cohort: The samples were routine care residues from random patients, anonymized 792 within 48 hours of collection, regardless of gender or hospitalization reason, collected in the 793 course of a month between the end of January and the end of February 2021. The Covid status 794 (PCR or positive serology) was unknown to the person performing the Jurkat-S&R-flow, ELISA 795 and HAT experiments. Those whole blood samples were kept at room temperature until being 796 used for HAT assays within 24 hours of obtaining them from the hospital. In trial experiments, 797 we had found that such samples could be stored for up to 5 days without any noticeable 798 difference in the performance of the HAT test.

After the whole blood samples had been used for HAT assays, the tubes were then spun, and the plasmas harvested into fresh tubes (to which sodium azide was added at a final concentration of 200 ug/ml). Those harvested plasmas were kept at 4°C until they were used to

802 perform the Jurkat-S&R-flow tests and ELISA tests.

803 <u>Capillary blood</u>: one of the authors of this study collected 50 μ L of his own blood by finger 804 pricking, using disposable lancets (Sarstedt ref 85.1016) on various days during the course of 805 his vaccination regimen with the Pfizer/BioNTech vaccine. At the time of collection, the blood 806 samples were diluted with 200 μ L of PBS + 5mM EDTA (Since whole blood is roughly 50% RBCs 807 and 50% plasma, this 1/5 dilution of the blood actually corresponds to a 1/10 dilution of the 808 plasma). The plasma was then separated from the RBCs after centrifugation, placed in another 809 tube with sodium azide, and stored at 4°C until the day of the assay.

810

811 Experiments on mouse sera

812 <u>Virus preparation and inactivation</u>

813 SARS-CoV2 was grown on Vero E6 cells (ATCC) in DMEM (Dutscher) supplemented with 100 U/mL penicillin, 100 µg/ml streptomycin (Invitrogen), and 2% heat inactivated fetal bovine 814 815 serum (Sigma). Viral stocks were propagated in 300 cm² flasks (Dutscher) in which 10³ tissue 816 culture infectious dose 50 (TCID₅₀) were inoculated in 100 ml of medium for 3 days at 37°C with 817 5% CO₂. Culture supernatants containing the viral stocks were harvested and inactivated with 818 BPL (Fischer) overnight at 4°C. Virus was then concentrated by ultracentrifugation at 25 000 rpm 819 (for 2 hours at 4°C) on a 20% sucrose cushion in Ultra-Clear centrifuge tubes (SW-32 Ti rotor, 820 Beckman). Pellets were resuspended in PBS, protein concentration was quantified by BCA 821 Protein Assay kit (Pierce). BPL-inactivated SARS-CoV2 stocks at protein concentrations ranging 822 from 1 to 5 μ g/ μ L were stored at -80°C until use.

823 <u>Mouse immunization</u>

Mice were injected intra-peritoneally with 15 µg of BPL-SARS-CoV2 in 250 µl of PBS, and then
challenged with the same amount at day 62. Mice were euthanized and serum was collected at
day 14 post-primary immunization and at day 7 post-secondary challenge. Those experiments
were conducted within the scope of the APAFIS licence n° 15236 delivered to Jean Charles
Guéry.

830

831 Experiments on Cat and Dog sera

Serum samples were collected from cats and dogs belonging to owners who developed COVID-19-like symptoms and subsequently tested positive for SARS-CoV-2 infection by RT-qPCR., at least one month after the owners' recoveries. Samples and data collections were conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee Sciences et Santé Animale n°115 (protocol code COVIFEL approved on 1 September 2020, registered under SSA_2020_010).

838 <u>Sero-neutralisation assay</u>

839 Serum samples and controls were heat-inactivated at 56 °C for 30 min, serially diluted in 840 DMEM starting at 1:10, mixed with an equal volume of SARS-CoV-2 stock (previously amplified 841 and titrated on Vero-E6 cells and diluted in DMEM to contain 2000 TCID₅₀/ml), incubated for 2 842 hours at 37 °C, and 100 μL transferred to tissue-culture 96 well plates plated with 12.000 Vero-843 E6 cells per well the day before the assay, in DMEM complemented with 10% of heat-844 inactivated fetal bovine serum and 1% of penicillin-streptomycin at 37 °C with 5% of CO2 845 (medium was removed before adding the virus-serum dilutions). After 60 minutes at 37°C, the 846 virus-serum dilutions were removed before adding DMEM complemented with 2% of heat-847 inactivated fetal bovine serum and 1% of penicillin-streptomycin. Cells were then incubated for 848 72 h at 37 °C with 5% of CO2. Individual wells were then screened by eye under the microscope 849 for cytopathic effects. Monoclonal anti-SARS-CoV CR3022 antibody (BEI Resources, NIAID, NIH) 850 was used as a positive control. PBS was used as a negative control. Experiments were carried 851 out in a biosafety level 3 facility at the National Veterinary School of Toulouse.

852

853 Experiments on virally-infected hamsters

854 Eight week-old female Syrian golden hamsters (Mesocricetus auratus, strain RiHan:AURA) 855 from Janviers's breeding Center (Le Genest, St Isle, France) were housed in an animal-biosafety 856 level 3 (A-BSL3), with ad libidum access to water and food. Animals were anesthetized with 857 isoflurane and inoculated intranasally with 10⁴ TCID₅₀ units of UCN1 SARS-CoV-2 strain split in 858 20µL in each nostril. SARS-CoV-2 strain UCN1 was amplified as described previously and used at 859 passage 2 (Monchatre-Leroy et al. 2021; Bessière, Wasniewski, et al. 2021). Non-infected 860 animals received the equivalent amount of PBS. Animals were weighted and clinically monitored 861 daily. Six animals from each group were anesthetized and euthanized by exsanguination at 15 862 dpi. Sera were harvested and aliquots were kept frozen until they were needed for the 863 experiments described here.

The animal experimentation protocols complied with the regulation 2010/63/CE of the European Parliament and of the council of 22 September 2010 on the protection of animals used for scientific purposes. These experiments were approved by the Anses/ENVA/UPEC ethic committee and the French Ministry of Research (Apafis n°24818-2020032710416319).

869 Ethical statement

870 All sera from the first cohort, and whole blood samples from the second cohort, were 871 obtained from the Toulouse hospital, where all patients give, by default, their consent for any 872 biological material left over to be used for research purposes after all the clinical tests 873 requested by doctors have been duly completed. Material transfer was done under a signed 874 agreement (CNRS n° 227232, CHU n° 20 427 C). This study was declared and approved by the 875 governing body of the Toulouse University Hospital with the agreement number RnIPH 2021-99, confirming that ethical requirements were fully respected.

- 876
- 877

878 Using such materials, we did not really have control over how representative our cohorts 879 may be, but this allowed us to circumvent the very stringent rules set by French laws regarding 880 the use of human materials for research (RIPH, Loi Jardé). Under those rules, setting up a clinical 881 trial involving biological materials of human origin would require many months of 882 administrative procedures and paperwork, as well as several hundreds of thousands of euros, 883 which we did not have access to.

884

885 For the same reason, the blood samples for the experiment shown on Figure 3A were 886 collected by one of the authors by simple finger-pricking. He did so on his own free will, without 887 the intervention of anybody else, thus circumventing the need for ethical approval.

- 888
- 889

890 Bibliography

- Abravanel, F., Miédouge, M., Chapuv-Regaud, S., Mansuv, J.-M. and Izopet, J. 2020. Clinical 891
- 892 performance of a rapid test compared to a microplate test to detect total anti SARS-CoV-2
- 893 antibodies directed to the spike protein. Journal of Clinical Virology 130, p. 104528.
- Abu-Raddad, L.J., Chemaitelly, H., Coyle, P., et al. 2021. SARS-CoV-2 reinfection in a cohort of 894 895 43,000 antibody-positive individuals followed for up to 35 weeks. *medRxiv*.
- 896 Adams, E.R., Ainsworth, M., Anand, R., et al. 2020. Antibody testing for COVID-19: A report
- 897 from the National COVID Scientific Advisory Panel. Wellcome Open Research 5, p. 139.
- 898 Amanat, F., Stadlbauer, D., Strohmeier, S., et al. 2020. A serological assay to detect SARS-CoV-
- 899 2 seroconversion in humans. *Nature Medicine* 26(7), pp. 1033–1036.
- 900 Barnes, C.O., Jette, C.A., Abernathy, M.E., et al. 2020. SARS-CoV-2 neutralizing antibody
- 901 structures inform therapeutic strategies. Nature 588(7839), pp. 682-687.
- 902 Bessière, P., Fusade-Boyer, M., Walch, M., et al. 2021. Household Cases Suggest That Cats
- 903 Belonging to Owners with COVID-19 Have a Limited Role in Virus Transmission. Viruses 904 13(4).
- 905 Bessière, P., Wasniewski, M., Picard-Meyer, E., et al. 2021. Intranasal type I interferon treatment
- 906 is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster 907 model. *BioRxiv*.
- 908 Chen, H. 2020. Susceptibility of ferrets, cats, dogs, and different domestic animals to SARS-909 coronavirus-2. BioRxiv.
- 910 Chen, Xinhua, Chen, Z., Azman, A.S., et al. 2021. Serological evidence of human infection with
- 911 SARS-CoV-2: a systematic review and meta-analysis. The Lancet. Global health 9(5), pp. e598-912 e609.
- 913 Dejnirattisai, W., Zhou, D., Ginn, H.M., et al. 2021. The antigenic anatomy of SARS-CoV-2
- receptor binding domain. Cell 184(8), p. 2183-2200.e22. 914
- 915 Dortet, L., Ronat, J.-B., Vauloup-Fellous, C., et al. 2021. Evaluating 10 Commercially Available
- SARS-CoV-2 Rapid Serological Tests by Use of the STARD (Standards for Reporting of 916

- 917 Diagnostic Accuracy Studies) Method. *Journal of Clinical Microbiology* 59(2).
- Dróżdż, M., Krzyżek, P., Dudek, B., Makuch, S., Janczura, A. and Paluch, E. 2021. Current State
 of Knowledge about Role of Pets in Zoonotic Transmission of SARS-CoV-2. *Viruses* 13(6).
- 919 Of Knowledge about Role of Pets in Zoonotic Transmission of SARS-Cov-2. Viruses 13(6).
- Egia-Mendikute, L., Bosch, A., Prieto-Fernández, E., et al. 2021. Sensitive detection of SARS CoV-2 seroconversion by flow cytometry reveals the presence of nucleoprotein-reactive
- antibodies in unexposed individuals. *Communications Biology* 4(1), p. 486.
- 923 Ertesvåg, N.U., Xiao, J., Zhou, F., et al. 2021. A Rapid Antibody Screening Haemagglutination
- 923 Ertesvag, N.U., Xiao, J., Zhou, F., et al. 2021. A Rapid Antibody Screening Haemagglutination
 924 Test for Predicting Immunity to Sars CoV-2 Variants of Concern. *Research square*.
- Fani, M., Teimoori, A. and Ghafari, S. 2020. Comparison of the COVID-2019 (SARS-CoV-2)
- pathogenesis with SARS-CoV and MERS-CoV infections. *Future virology*.
- 927 Farnsworth, C.W. and Anderson, N.W. 2020. SARS-CoV-2 Serology: Much Hype, Little Data.
 928 *Clinical Chemistry* 66(7), pp. 875–877.
- Feng, S., Phillips, D.J., White, T., et al. 2021. Correlates of protection against symptomatic and
 asymptomatic SARS-CoV-2 infection. *medRxiv*.
- Garcia-Beltran, W.F., Lam, E.C., Astudillo, M.G., et al. 2021. COVID-19-neutralizing antibodies
 predict disease severity and survival. *Cell* 184(2), p. 476–488.e11.
- 933 Goh, Y.S., Ng, L.F.P. and Renia, L. 2021. A flow cytometry-based assay for serological
- detection of anti-spike antibodies in COVID-19 patients. *STAR Protocols* 2(3), p. 100671.
- 935 Grzelak, L., Temmam, S., Planchais, C., et al. 2020. A comparison of four serological assays for
- 936 detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations.
- 937 Science Translational Medicine 12(559).
- Hambach, J., Stähler, T., Eden, T., et al. 2021. A simple, sensitive, and low-cost FACS assay for
- detecting antibodies against the native SARS-CoV-2 spike protein. *Immunity, inflammation and disease* 9(3), pp. 905–917.
- 941 Harvey, R.A., Rassen, J.A., Kabelac, C.A., et al. 2021. Association of SARS-CoV-2 Seropositive
- 942 Antibody Test With Risk of Future Infection. JAMA internal medicine 181(5), pp. 672–679.
- 943 Harvey, W.T., Carabelli, A.M., Jackson, B., et al. 2021. SARS-CoV-2 variants, spike mutations
- and immune escape. *Nature Reviews. Microbiology* 19(7), pp. 409–424.
- Hickey, M.J., Valenzuela, N.M. and Reed, E.F. 2016. Alloantibody generation and effector
- 946 function following sensitization to human leukocyte antigen. *Frontiers in immunology* 7, p. 30.
- Horndler, L., Delgado, P., Abia, D., et al. 2021. Flow cytometry multiplexed method for the
- 948 detection of neutralizing human antibodies to the native SARS-CoV-2 spike protein. *EMBO* 949 *Molecular Medicine* 13(3), p. e13549.
- 950 Huang, K.-Y.A., Tan, T.K., Chen, T.-H., et al. 2021. Breadth and function of antibody response
- to acute SARS-CoV-2 infection in humans. *PLoS Pathogens* 17(2), p. e1009352.
- 952 Jayathilaka, D., Jeewandara, C., Gomes, L., et al. 2021. Comparison of kinetics of immune
- 953 responses to SARS-CoV-2 proteins in individuals with varying severity of infection and
- 954 following a single dose of the AZD1222. *medRxiv*.
- 955 Jeewandara, C., Kamaladasa, A., Pushpakumara, P.D., et al. 2021. Immune responses to a single
- dose of the AZD1222/Covishield vaccine in health care workers. *Nature Communications* 12(1),p. 4617.
- ⁹⁵⁸ Jeffery-Smith, A., Iyanger, N., Williams, S.V., et al. 2021. Antibodies to SARS-CoV-2 protect
- against re-infection during outbreaks in care homes, September and October 2020. *Euro Surveillance* 26(5).
- 961 Kamaladasa, A., Gunasekara, B., Jeewandara, C., et al. 2021. Comparison of two assays to detect
- 962 IgG antibodies to the receptor binding domain of SARS-CoV-2 as a surrogate marker for
- assessing neutralizing antibodies in COVID-19 patients. *International Journal of Infectious*
- 964 *Diseases* 109, pp. 85–89.
- 965 Karahan, G.E., Claas, F.H.J. and Heidt, S. 2020. Pre-existing Alloreactive T and B Cells and

- 966 Their Possible Relevance for Pre-transplant Risk Estimation in Kidney Transplant Recipients.
- 967 *Frontiers in medicine* 7, p. 340.
- 968 Khan, S., Nakajima, R., Jain, A., et al. 2020. Analysis of Serologic Cross-Reactivity Between
- 969 Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray.
 970 *BioRxiv*.
- 971 Khoury, D.S., Cromer, D., Reynaldi, A., et al. 2021. Neutralizing antibody levels are highly
- predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nature Medicine*27(7), pp. 1205–1211.
- 974 Koopmans, M. and Haagmans, B. 2020. Assessing the extent of SARS-CoV-2 circulation
- 975 through serological studies. *Nature Medicine* 26(8), pp. 1171–1172.
- 276 Lamikanra, A., Nguyen, D., Simmonds, P., et al. 2021. Comparability of six different
- 977 immunoassays measuring SARS-CoV-2 antibodies with neutralising antibody levels in
 978 convalescent plasma: from utility to prediction. *Transfusion*.
- 279 Lapuente, D., Maier, C., Irrgang, P., et al. 2021. Rapid response flow cytometric assay for the
- 980 detection of antibody responses to SARS-CoV-2. European Journal of Clinical Microbiology &
- 981 *Infectious Diseases* 40(4), pp. 751–759.
- 982 Letizia, A.G., Ge, Y., Vangeti, S., et al. 2021. SARS-CoV-2 Seropositivity and Subsequent
- 983 Infection Risk in Healthy Young Adults: A Prospective Cohort Study. SSRN Electronic Journal.
- 284 Long, Q.-X., Tang, X.-J., Shi, Q.-L., et al. 2020. Clinical and immunological assessment of
- asymptomatic SARS-CoV-2 infections. *Nature Medicine* 26(8), pp. 1200–1204.
- 986 Lumley, S.F., O'Donnell, D., Stoesser, N.E., et al. 2021. Antibody Status and Incidence of
- 987 SARS-CoV-2 Infection in Health Care Workers. *The New England Journal of Medicine* 384(6),
 988 pp. 533–540.
- 989 ter Meulen, J., van den Brink, E.N., Poon, L.L.M., et al. 2006. Human monoclonal antibody
- combination against SARS coronavirus: synergy and coverage of escape mutants. *PLoS Medicine* 3(7), p. e237.
- 992 Mohit, E., Rostami, Z. and Vahidi, H. 2021. A comparative review of immunoassays for COVID-
- 993 19 detection. *Expert review of clinical immunology*.
- 994 Monchatre-Leroy, E., Lesellier, S., Wasniewski, M., et al. 2021. Hamster and ferret experimental
- 995 infection with intranasal low dose of a single strain of SARS-CoV-2. *The Journal of General*996 *Virology* 102(3).
- 997 Moshe, M., Daunt, A., Flower, B., et al. 2021. SARS-CoV-2 lateral flow assays for possible use
- in national covid-19 seroprevalence surveys (React 2): diagnostic accuracy study. *BMJ (Clinical Research Ed.)* 372, p. n423.
- 1000 Ng, K.W., Faulkner, N., Cornish, G.H., et al. 2020. Preexisting and de novo humoral immunity to
- 1001 SARS-CoV-2 in humans. *Science* 370(6522), pp. 1339–1343.
- 1002 Piccoli, L., Park, Y.-J., Tortorici, M.A., et al. 2020. Mapping Neutralizing and Immunodominant
- 1003 Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-
- 1004 Resolution Serology. Cell 183(4), p. 1024–1042.e21.
- 1005 Piñero, P., Marco De La Calle, F.M., Horndler, L., et al. 2021. Flow cytometry detection of
- 1006 sustained humoral immune response (IgG + IgA) against native spike glycoprotein in
- asymptomatic/mild SARS-CoV-2 infection. *Scientific Reports* 11(1), p. 10716.
- 1008 Robbiani, D.F., Gaebler, C., Muecksch, F., et al. 2020. Convergent antibody responses to SARS-
- 1009 CoV-2 in convalescent individuals. *Nature* 584(7821), pp. 437–442.
- Sit, T.H.C., Brackman, C.J., Ip, S.M., et al. 2020. Infection of dogs with SARS-CoV-2. *Nature* 586(7831), pp. 776–778.
- 1012 Townsend, A., Rijal, P., Xiao, J., et al. 2021. A haemagglutination test for rapid detection of
- 1013 antibodies to SARS-CoV-2. *Nature Communications* 12(1), p. 1951.
- 1014 Wu, Z., Harrich, D., Li, Z., Hu, D. and Li, D. 2021. The unique features of SARS-CoV-2

- transmission: Comparison with SARS-CoV, MERS-CoV and 2009 H1N1 pandemic influenza
- 1016 virus. *Reviews in medical virology* 31(2), p. e2171.
- 1017 Zennou, V., Petit, C., Guetard, D., Nerhbass, U., Montagnier, L. and Charneau, P. 2000. HIV-1
- 1018 genome nuclear import is mediated by a central DNA flap. *Cell* 101(2), pp. 173–185.
- 1019 Zhou, D., Duyvesteyn, H.M.E., Chen, C.-P., et al. 2020. Structural basis for the neutralization of
- 1020 SARS-CoV-2 by an antibody from a convalescent patient. *Nature Structural & Molecular*
- 1021 *Biology* 27(10), pp. 950–958.
- 1022

1023 Supplementary material

1024



2.

- Figure S1: Using a flow cytometer with a 561 nm Yellow-Green laser improves the mCherry
 signals
- 1029The same samples shown on Figure 1 were also analyzed on a Fortessa flow cytometer. The1030561 nm yellow-green laser was used for the excitation of the mCherry fluorescent protein,1031which led to much brighter signals, and thus to much easier separation of the Jurkat-R (mCherry1032pos) and Jurkat-S (mCherry neg) populations than when the samples were acquired on a1033FACScalibur.
- As in figure 1, the numbers in the upper right corners of the histogram overlays plots correspond to the GMFI of the two histograms (Red: Jurkat-R; green: Jurkat-S), and the big red numbers to the left of the plots to the RSS. Of note, although the GMFI values were much higher on the Fortessa than those recorded on the FACScalibur, the RSS values of the various samples were all very similar between the two machines.
- 1039

1040 After the samples had been run on both flow cytometers, those were fixed in 1% 1041 formaldehyde by adding an equal volume of PBS + 2% formaldehyde to the remainder of each 1042 sample. The tubes were then stored à 4°C for 4 days before re-analyzing them on both 1043 cytometers. As can be seen on the right hand side of the figure, the red fluorescence of the 1044 mCherry was still detectable on the Fortessa after this procedure of fixation, despite the 1045 intensity of the signals having dropped by about 7 fold. On the FACScalibur, however, this drop 1046 of the mCherry fluorescent signals precluded the separation of the Jurkat-S from the Jurkat-R 1047 cells. If samples are to be fixed, performing the Jurkat-R&S-flow test will thus require access to a 1048 flow cytometer equipped with a 561 nm Yellow-Green laser. As an alternative, we are currently 1049 exploring the possibility of transforming the Jurkat-S&R-flow test into a Jurkat-S&G-flow test, 1050 where the negative control cells would be expressing GFP, which is excited at 488 nm, and using 1051 secondary antibodies conjugated to red fluorochromes such as Alexa647, excited by a 633 nm 1052 red laser, for the detection of the primary antibodies.

1053

Of note, in the dot plots of the Positive and Strong Positive fixed samples, faint clouds of FL1 negative cells can be seen in the mCherry neg window. Those presumably correspond to Jurkat-R cells which were dead before the fixation step, and from which the mCherry had thus leaked out. When analyzing populations of live cells, such cells are gated out with the To-pro 3 live stain, but this no longer works for population of fixed cells. This small problem could probably be circumvented using a fixable dead cell staining dye such as the LIVE/DEAD Fixable Far Red stain (ThermoFischer L34973).

- 1061
- 1062



RBD binding class	1			
mAbs (ng/ml)	FI3A	FI3A RT	C121	
1000	308.9	543.91	333.84	
316	259.88	370.96	304.7	
100	149.77	146.97	231.7	
32	58.16	55.4	113.8	
10	22.11	23.28	47.65	
3	9.31	8.08	20.53	
1	3.48	3.69	9.24	
0.3	0.24	1 61	3 37	

dilution	20/130	20/130 RT	0102-1
1/100	254.97	413.59	54.75
1/300	153.37	264.69	20.26
1/900	69.78	137.84	5.78
1/2700	26.57	57.94	1.12
1/8100	9.21	23.52	-2.37
1/24300	0.61	8.11	-2.32
1/72900	-1.82	3.33	-1.79
1/218700	-2.91	1.28	-0.73

- 1063
- 1064

Figure S2: Incubation of the samples at room temperature for the first part of the primary
 staining step markedly improves the staining signals for most antibodies.

For a large fraction of monoclonal and polyclonal antibodies reacting with the Spike protein expressed at the surface of cells, we have repeatedly observed that a step of incubation at room temperature can result in a marked improvement of the staining signals compared to performing the staining continuously on ice.

1071 For this experiment, we selected a panel of 5 monoclonal antibodies reacting with different 1072 sites of the spike RBD domain, a panel of 4 plasmas reacting with various intensities, as well the 1073 20/130 reference serum.

1074 For all the samples, we performed eight steps of 3-fold dilutions, and placed 10 ul of the 1075 diluted samples in two parallel U bottom 96 well plates. The first plate was kept at room 1076 temperature (RT) whilst the other one was placed on ice. The Jurkat-S&R mix was then added to 1077 the wells of the plate at room temperature. The tube was then placed on ice for a few minutes, 1078 before distributing the mix in the wells of the second plate. After 30 minutes, the plate which 1079 had been sitting at room temperature was also placed on ice, and incubated for another 30 1080 minutes. The rest of the staining procedure was then exactly the same for the two plates, all 1081 performed in the cold as described in M&M.

	IgGAM				lgG			IgA		lgM							
	Sample ID	GMFI Jurkat R	GMFI Jurkat S	specific stain (J- S-J-R)	GMFI Jurkat R	GMFI Jurkat S	specific stain (J- S - J-R)	GMFI Jurkat R	GMFI Jurkat- S	specific stain (J- S - J-R)	GMFI Jurkat R	GMFI Jurkat S	specific stain (J- S - J-R)	G+A+M	Fraction IgG signal	Fraction IgA signal	Fraction IgM signal
	neg	1.87	2.01	0.14	1.95	1.99	0.04	1.79	2.13	0.34	1.89	1.98	0.09	0.47			
	30/120	3.19	760	756.81	3.59	763	759.41	2.11	63.2	61.09	2.74	640	637.26	1457.76	0.52	0.04	0.44
	<j14-3< td=""><td>5.1</td><td>51.6</td><td>46.5</td><td>7.47</td><td>57.2</td><td>49.73</td><td>3.08</td><td>29.1</td><td>26.02</td><td>2.55</td><td>8.65</td><td>6.1</td><td>81.85</td><td>0.61</td><td>0.32</td><td>0.07</td></j14-3<>	5.1	51.6	46.5	7.47	57.2	49.73	3.08	29.1	26.02	2.55	8.65	6.1	81.85	0.61	0.32	0.07
	<j14-29< td=""><td>4.59</td><td>738</td><td>733.41</td><td>5.16</td><td>919</td><td>913.84</td><td>2.77</td><td>122</td><td>119.23</td><td>2.54</td><td>203</td><td>200.46</td><td>1233.53</td><td>0.74</td><td>0.10</td><td>0.16</td></j14-29<>	4.59	738	733.41	5.16	919	913.84	2.77	122	119.23	2.54	203	200.46	1233.53	0.74	0.10	0.16
	<j14-32< td=""><td>4.71</td><td>1692</td><td>1687.29</td><td>5.25</td><td>2350</td><td>2344.75</td><td>4.01</td><td>610</td><td>605.99</td><td>2.56</td><td>402</td><td>399.44</td><td>3350.18</td><td>0.70</td><td>0.18</td><td>0.12</td></j14-32<>	4.71	1692	1687.29	5.25	2350	2344.75	4.01	610	605.99	2.56	402	399.44	3350.18	0.70	0.18	0.12
6	<j14-35< td=""><td>4.65</td><td>198</td><td>193.35</td><td>4.82</td><td>209</td><td>204.18</td><td>1.97</td><td>52.6</td><td>50.63</td><td>3.14</td><td>13.1</td><td>9.96</td><td>264.77</td><td>0.77</td><td>0.19</td><td>0.04</td></j14-35<>	4.65	198	193.35	4.82	209	204.18	1.97	52.6	50.63	3.14	13.1	9.96	264.77	0.77	0.19	0.04
Sera	<j14-109< td=""><td>6.52</td><td>852</td><td>845.48</td><td>6.23</td><td>1082</td><td>1075.77</td><td>2.61</td><td>179</td><td>176.39</td><td>4.55</td><td>126</td><td>121.45</td><td>1373.61</td><td>0.78</td><td>0.13</td><td>0.09</td></j14-109<>	6.52	852	845.48	6.23	1082	1075.77	2.61	179	176.39	4.55	126	121.45	1373.61	0.78	0.13	0.09
	<j14-130< td=""><td>8.7</td><td>150</td><td>141.3</td><td>9.46</td><td>151</td><td>141.54</td><td>3.28</td><td>45.7</td><td>42.42</td><td>5.25</td><td>58.1</td><td>52.85</td><td>236.81</td><td>0.60</td><td>0.18</td><td>0.22</td></j14-130<>	8.7	150	141.3	9.46	151	141.54	3.28	45.7	42.42	5.25	58.1	52.85	236.81	0.60	0.18	0.22
	>J14-40	4.84	54.9	50.06	6.07	54.3	48.23	2.18	12	9.82	2.76	29.1	26.34	84.39	0.57	0.12	0.31
	neg-2213	10.5	33.3	22.8	12.3	43.3	31	3.21	6.58	3.37	6.12	8.77	2.65	37.02	0.84	0.09	0.07
	neg-2649	19.2	41.4	22.2	24.7	56.2	31.5	6.32	9.59	3.27	6.15	9.62	3.47	38.24	0.82	0.09	0.09
	2	438	1427	989	577	1846	1269	59.4	469	409.6	739	1333	594	2272.60	0.56	0.18	0.26
	18	7.82	84.9	77.08	11.3	101	89.7	2.67	33.4	30.73	4.89	12.7	7.81	128.24	0.70	0.24	0.06
	19	2.02	2.2	0.18	2.07	2.15	0.08	1.82	2.18	0.36	1.83	1.96	0.13	0.57			
	36	4.53	88.7	84.17	5.01	90.2	85.19	2.38	48.5	46.12	3.61	10.4	6.79	138.10	0.62	0.33	0.05
	47	3.47	139	135.53	3.65	141	137.35	2.15	47.1	44.95	2.8	42.2	39.4	221.70	0.62	0.20	0.18
	56	9.03	25.7	16.67	9.48	26.8	17.32	2.56	17.2	14.64	7.16	11.2	4.04	36.00	0.48	0.41	0.11
	57	5.84	25.5	19.66	7.04	26.7	19.66	2.17	8.87	6.7	4.55	13.9	9.35	35.71	0.55	0.19	0.26
	73	3.87	130	126.13	3.61	159	155.39	1.91	4.35	2.44	3.1	4.64	1.54	159.37	0.98	0.02	0.01
	80	2.5	82	79.5	3.07	99.1	96.03	2.06	2.75	0.69	2.21	2.56	0.35	97.07	0.99	0.01	0.00
	83	3.13	1674	1670.87	3.69	1900	1896.31	2.21	542	539.79	2.4	629	626.6	3062.70	0.62	0.18	0.20
	88	3.74	1110	1106.26	4.18	1297	1292.82	2.51	159	156.49	3.03	632	628.97	2078.28	0.62	0.08	0.30
Plasmas	108	3.53	7.65	4.12	4.22	9.66	5.44	2.08	2.61	0.53	2.6	3.58	0.98	6.95			
	123	54.5	75.6	21.1	51.6	71.4	19.8	4.22	6.14	1.92	43.5	61.1	17.6	39.32	0.62	0.08	0.30
	161	2.91	5.84	2.93	6.17	11.1	4.93	2.08	2.59	0.51	2.09	2.25	0.16	5.60			
	166	101	162	61	109	176	67	27.2	35.3	8.1	46.5	68.9	22.4	97.50	0.69	0.08	0.23
	174	3.11	190	186.89	4.43	228	223.57	2.45	50.1	47.65	2.19	42.3	40.11	311.33	0.72	0.15	0.13
	177	7.9	1945	1937.1	8.04	2303	2294.96	2.32	581	578.68	7.58	699	691.42	3565.06	0.64	0.16	0.19
	227	4.12	77	72.88	5.31	51.4	46.09	2.83	6.19	3.36	3	73.8	70.8	120.25	0.38	0.03	0.59
	232	11	131	120	12.6	169	156.4	6.21	9.13	2.92	4.84	6.83	1.99	161.31	0.97	0.02	0.01
	241	4.11	2411	2406.89	4.61	2860	2855.39	2.6	608	605.4	2.83	47.8	44.97	3505.76	0.81	0.17	0.01
	247	13.8	23.3	9.5	21.6	31.7	10.1	8.87	15.7	6.83	3.5	5.88	2.38	19.31	0.52	0.35	0.12
	253	3.98	28.2	24.22	5.22	33	27.78	2.43	10.7	8.27	2.43	2.9	0.47	36.52	0.76	0.23	0.01
	260	23.2	33.9	10.7	30.8	44.1	13.3	29.4	43	13.6	5.98	7.61	1.63	28.53	0.47	0.48	0.06

1083

Table S1: Example of isotyping performed on a representative set of various serum andplasma samples.

As can be seen on the right hand side portion of the table, comparison of samples from different patients shows that there can be large variations in the proportions of Ig-G,-A and -M. Because polyclonal secondary antibodies will not all react with their targeted primary antibodies with the same efficiency, however, the actuals signals for the various subclasses of antibodies should not be taken as a true reflection of the amounts of each subclass of antibody.

1091 If a more quantitative evaluation was needed, monoclonal secondary antibodies could be 1092 used instead of polyclonal reagents, making sure that all those isotypes-specific secondary 1093 monoclonal antibodies were being used well above the saturating concentration, and 1094 conjugated to similar amounts of the same fluorochrome. This would, however, increase the 1095 cost of the procedure considerably.